Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

Vaxcyte, formerly known as SutroVax, announced participation in the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 11:00 a.m. ET. The company aims to enhance global health through innovative vaccines targeting infectious diseases. Their lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease. Vaxcyte's platform, XpressCF™, enables advanced vaccine development, including candidates for Group A Strep infections and periodontal disease. Access the live webcast and replay via their website.

FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCF™ platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains, including newly emerging strains responsible for IPD and antibiotic resistance; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.

Contact:
Andrew Guggenhime, Chief Financial Officer & Chief Business Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

FAQ

What is Vaxcyte's lead vaccine candidate?

Vaxcyte's lead vaccine candidate is VAX-24, a preclinical 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease.

When will Vaxcyte participate in the Cantor Virtual Global Healthcare Conference?

Vaxcyte will participate in the conference on September 16, 2020, at 11:00 a.m. ET.

How can I access the Vaxcyte conference webcast?

The Vaxcyte conference webcast can be accessed through the Investors & Media section of their website.

What is the purpose of Vaxcyte's XpressCF™ platform?

The XpressCF™ platform enables the design and production of protein carriers and antigens, critical components for vaccine development.

What other vaccine candidates are in Vaxcyte's pipeline?

Vaxcyte's pipeline includes VAX-XP for expanded pneumococcal coverage, VAX-A1 for Group A Strep, and VAX-PG for periodontal disease.